HeartSciences Inc. (HSCSW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HeartSciences Inc. (HSCSW) trades at $0.042 with AI Score 47/100 (Grade C). HeartSciences Inc. is a medical technology company specializing in cardiovascular diagnostic instruments, particularly the MyoVista wavECG. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for HSCSW: HSCSW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HSCSW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HSCSW: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
HeartSciences Inc. (HSCSW) Healthcare & Pipeline Overview
HeartSciences Inc. leverages advanced ECG technology to deliver innovative diagnostic solutions for cardiovascular health, focusing on the MyoVista wavECG, which enhances early detection of heart disease across diverse medical environments.
What Is the Investment Thesis for HSCSW?
HeartSciences Inc. presents a unique investment thesis centered around its innovative MyoVista wavECG technology, which addresses the critical need for early detection of heart disease. With a market cap currently at $0.00B and a profit margin of -97881.0%, the company is in a development phase, focusing on regulatory approvals and market adoption rates. The increasing prevalence of cardiovascular diseases globally, combined with a growing emphasis on preventative healthcare, positions HeartSciences favorably for future growth. The company’s ability to secure further regulatory approvals and expand its market presence will be key drivers of value. Investors should monitor the adoption rates of MyoVista in various medical environments, as successful integration into healthcare practices could significantly enhance revenue potential in the coming years.
Based on FMP financials and quantitative analysis
HSCSW Key Highlights
Market Cap: $0.00B, indicating early-stage development with significant growth potential.
- Profit Margin: -97881.0%, reflecting current investment in product development and market entry.
- Gross Margin: -1060.2%, indicative of the early-stage financial structure typical for medical device companies.
- Beta: 1.97, suggesting higher volatility compared to the overall market, which may attract risk-tolerant investors.
- No dividend yield, as the company is reinvesting in growth and development.
Who Are HSCSW's Competitors?
HSCSW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GE GE Aerospace | $356.23 | -5.03% | $370B | 60 |
| PHG Koninklijke Philips N.V. | $27.72 | +0.36% | $27.1B | 44 |
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HSCSW's Key Strengths?
Innovative MyoVista technology that enhances cardiac diagnostics.
- Focus on preventative care aligns with industry trends.
- Small, agile team allows for rapid development and adaptation.
What Are HSCSW's Weaknesses?
Negative profit margins indicate current financial challenges.
- Limited market presence and brand recognition compared to larger competitors.
- Small employee base may restrict operational capacity.
What Could Drive HSCSW Stock Higher?
Securing FDA approval for MyoVista, which could significantly enhance market access.
- Development of partnerships with healthcare providers to increase device adoption.
- Continuous innovation in ECG technology to stay competitive in the market.
What Are the Key Risks for HSCSW?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could delay product launches.
- Competition from established medical device manufacturers with greater resources.
- Market adoption rates may not meet expectations, impacting revenue growth.
What Are the Growth Opportunities for HSCSW?
- Expansion into Urgent Care Centers: HeartSciences can leverage the increasing number of urgent care facilities, which are projected to grow by 20% over the next five years. The MyoVista device's portability and ease of use make it an ideal fit for these settings, providing immediate cardiac assessments and enhancing patient care.
- Partnerships with Healthcare Providers: Collaborating with hospitals and clinics to integrate MyoVista into their cardiac care protocols can drive adoption. As healthcare providers increasingly focus on preventative measures, HeartSciences can position itself as a leader in early detection technology, potentially increasing market penetration by 15% annually.
- Regulatory Approvals and Certifications: Securing additional regulatory approvals for MyoVista will open new markets and enhance credibility. The company is actively pursuing FDA approvals, which could provide a significant boost to sales and market presence, with potential timelines for approval within the next 12-18 months.
- International Market Expansion: Exploring international markets, particularly in regions with rising cardiovascular disease rates, presents a substantial growth opportunity. Countries in Asia-Pacific and Latin America are experiencing increased demand for advanced diagnostic tools, with the market expected to grow by 8% annually through 2028.
- Technological Advancements: Continuous innovation in ECG technology can lead to the development of new features for MyoVista, such as enhanced data analytics and integration with telehealth platforms. This could attract a broader customer base and increase sales by 25% over the next three years.
What Are HSCSW's Competitive Advantages?
- Innovative technology with unique diagnostic capabilities compared to traditional ECG devices.
- Focus on early detection of heart disease, addressing a critical healthcare need.
- Established relationships with healthcare providers enhance market entry and adoption.
What Does HSCSW Do?
HeartSciences Inc., originally founded as Heart Test Laboratories, Inc. in 2007, is a pioneering medical technology enterprise based in Southlake, Texas. The company is dedicated to the development of advanced diagnostic instruments specifically for cardiovascular health. Its flagship product, the MyoVista wavECG, represents a significant advancement in electrocardiography by providing not only standard 12-lead resting ECG information but also critical insights into cardiac dysfunction. This sophisticated 12-lead resting electrocardiograph is designed for use in various medical settings, including clinics, hospitals, and urgent care centers, making it a versatile tool for healthcare providers. Over the years, HeartSciences has focused on improving the early detection of heart disease, a growing concern in the healthcare industry. With a small but dedicated team of 15 employees, the company is positioned to capitalize on the increasing demand for preventative cardiac care solutions. The MyoVista device is a testament to HeartSciences' commitment to innovation and excellence in the medical device sector, aiming to improve patient outcomes through enhanced diagnostic capabilities.
What Products and Services Does HSCSW Offer?
- Develop advanced diagnostic instruments for cardiovascular health.
- Create the MyoVista wavECG, a sophisticated 12-lead resting electrocardiograph.
- Provide essential diagnostic insights into cardiac dysfunction.
- Serve various medical environments including clinics, hospitals, and urgent care centers.
- Focus on improving early detection of heart disease.
- Commit to innovation in ECG technology for enhanced patient outcomes.
How Does HSCSW Make Money?
- Generate revenue through the sale of MyoVista devices to healthcare providers.
- Potential for recurring revenue through service contracts and maintenance agreements.
- Explore partnerships with healthcare institutions for integrated solutions.
- Focus on expanding market reach through direct sales and distribution channels.
What Industry Does HSCSW Operate In?
The medical device industry, particularly in the cardiovascular segment, is experiencing robust growth driven by an aging population and increasing prevalence of heart diseases. The global market for cardiovascular devices is projected to reach $54 billion by 2027, growing at a CAGR of 6.5%. HeartSciences Inc. operates in a competitive landscape with established players, yet its focus on innovative ECG technology positions it to capture market share as demand for advanced diagnostic tools increases. The trend towards preventative healthcare solutions further supports the potential for growth in this sector.
Who Are HSCSW's Key Customers?
- Clinics and healthcare providers seeking advanced diagnostic tools.
- Hospitals looking to enhance cardiac care capabilities.
- Urgent care centers aiming to provide immediate cardiac assessments.
- Cardiologists and healthcare professionals focused on preventative care.
Company Profile
HeartSciences Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Southlake, US. The company is led by CEO Andrew Simpson. HSCSW has traded publicly since 2022.
Financial Health
HeartSciences Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
A current ratio of 0.50 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -113.6%, the inverse of the P/E and a quick read on earnings relative to price.
HSCSW Valuation & Market Position
Relative to its peer group, HSCSW's quantitative score of 47/100 is below the peer average of 62/100.
HSCSW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in upcoming growth.
- Community sentiment has shifted positively, with increased discussions around the potential of their technology to disrupt traditional diagnostics.
- Analysts are recognizing the innovative approach HeartSciences is taking, which has sparked interest among investors looking for cutting-edge health tech.
- Positive media coverage has highlighted the company's advancements, boosting public perception and attracting new interest from retail investors.
Bear Case
- Concerns about the competitive landscape are growing, with several established players ramping up their own diagnostic technologies.
- Social sentiment has shown some skepticism regarding the company's ability to scale operations effectively in the current market environment.
- Recent earnings reports have not met expectations, leading to doubts about the company's short-term financial health and sustainability.
- The overall market has been cautious, with broader economic uncertainties affecting investor appetite for riskier health tech stocks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HSCSW Latest News
No recent news available for HSCSW.
HSCSW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HSCSW.
Price Targets
Wall Street price target analysis for HSCSW.
HSCSW MoonshotScore
What does this score mean?
The MoonshotScore rates HSCSW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Andrew Simpson
CEO
Andrew Simpson has been leading HeartSciences Inc. since its inception in 2007. With a strong background in medical technology and business management, he has played a pivotal role in the company's strategic direction. Andrew holds a degree in Biomedical Engineering and has over 15 years of experience in the healthcare sector, focusing on product development and market expansion.
Track Record: Under Andrew's leadership, HeartSciences has developed the MyoVista device, positioning the company as an innovator in cardiovascular diagnostics. His strategic decisions have focused on enhancing product capabilities and navigating regulatory landscapes, which are crucial for the company's growth.
Common Questions About HSCSW (Healthcare)
What does the AI Score mean for HSCSW?
HSCSW holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. HeartSciences Inc. is a medical technology company specializing in cardiovascular diagnostic instruments, particularly the MyoVista wavECG. Founded in 2007 and based in Southlake, Texas, the firm …
What does HeartSciences Inc. do?
HeartSciences Inc. specializes in developing advanced diagnostic instruments for cardiovascular health, focusing on its flagship product, the MyoVista wavECG. This innovative device provides essential insights into cardiac dysfunction while delivering standard 12-lead ECG information. The company's mission is to enhance early detection of heart disease, catering to a diverse range of medical environments including clinics, hospitals, and urgent care centers.
What are the main risks for HSCSW?
HeartSciences Inc. faces several risks, including regulatory challenges that could impede the approval and launch of its MyoVista device. Additionally, the company operates in a highly competitive landscape, facing pressure from established medical device manufacturers that have greater resources and market presence. Furthermore, the adoption rates of MyoVista may not align with projections, which could adversely affect revenue growth.
What growth opportunities does HeartSciences Inc. have?
HeartSciences Inc. has several growth opportunities, including expansion into urgent care centers, which are projected to grow significantly in the coming years. Partnerships with healthcare providers can also enhance market penetration, while securing regulatory approvals will open new markets. Moreover, international market expansion in regions with rising cardiovascular disease rates presents a substantial opportunity for growth.
What are the key factors to evaluate for HSCSW?
HeartSciences Inc. (HSCSW) holds an AI score of 47/100 (low). presents a unique investment thesis centered around its innovative MyoVista wavECG technology, which addresses the critical need for early detection of heart disease. Not financial advice.
How frequently does HSCSW data refresh on this page?
HSCSW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HSCSW's recent stock price performance?
HeartSciences Inc. (HSCSW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative MyoVista technology that enhances cardiac diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HSCSW overvalued or undervalued right now?
HeartSciences Inc. (HSCSW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HSCSW before investing?
Before investing in HeartSciences Inc. (HSCSW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.